BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

8510 related articles for article (PubMed ID: 12662126)

  • 1. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
    Plosker GL; Figgitt DP
    Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rituximab: a review of its use in chronic lymphocytic leukaemia, low-grade or follicular lymphoma and diffuse large B-cell lymphoma.
    Keating GM
    Drugs; 2010 Jul; 70(11):1445-76. PubMed ID: 20614951
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study.
    Palanca-Wessels MC; Czuczman M; Salles G; Assouline S; Sehn LH; Flinn I; Patel MR; Sangha R; Hagenbeek A; Advani R; Tilly H; Casasnovas O; Press OW; Yalamanchili S; Kahn R; Dere RC; Lu D; Jones S; Jones C; Chu YW; Morschhauser F
    Lancet Oncol; 2015 Jun; 16(6):704-15. PubMed ID: 25925619
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Spotlight on rituximab in chronic lymphocytic leukemia, low-grade or follicular lymphoma, and diffuse large B-cell lymphoma.
    Keating GM
    BioDrugs; 2011 Feb; 25(1):55-61. PubMed ID: 21222497
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
    Cvetković RS; Perry CM
    Drugs; 2006; 66(6):791-820. PubMed ID: 16706552
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study.
    Younes A; Thieblemont C; Morschhauser F; Flinn I; Friedberg JW; Amorim S; Hivert B; Westin J; Vermeulen J; Bandyopadhyay N; de Vries R; Balasubramanian S; Hellemans P; Smit JW; Fourneau N; Oki Y
    Lancet Oncol; 2014 Aug; 15(9):1019-26. PubMed ID: 25042202
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The therapeutic use of rituximab in non-Hodgkin's lymphoma.
    Marcus R; Hagenbeek A
    Eur J Haematol Suppl; 2007 Jan; (67):5-14. PubMed ID: 17206982
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
    Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ
    Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bendamustine for patients with indolent B cell lymphoid malignancies including chronic lymphocytic leukaemia.
    Vidal L; Gafter-Gvili A; Gurion R; Raanani P; Dreyling M; Shpilberg O
    Cochrane Database Syst Rev; 2012 Sep; 2012(9):CD009045. PubMed ID: 22972131
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunochemotherapy in indolent non-Hodgkin's lymphoma.
    Czuczman MS
    Semin Oncol; 2002 Apr; 29(2 Suppl 6):11-7. PubMed ID: 12040529
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma.
    Vose JM; Link BK; Grossbard ML; Czuczman M; Grillo-Lopez A; Gilman P; Lowe A; Kunkel LA; Fisher RI
    J Clin Oncol; 2001 Jan; 19(2):389-97. PubMed ID: 11208830
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monoclonal antibodies in the treatment of non-Hodgkin's lymphoma.
    Fanale MA; Younes A
    Drugs; 2007; 67(3):333-50. PubMed ID: 17335294
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Spotlight on rituximab in non-Hodgkin lymphoma and chronic lymphocytic leukemia.
    Cvetković RS; Perry CM
    BioDrugs; 2006; 20(4):253-7. PubMed ID: 16831024
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Iodine-131 Tositumomab: (131)I-anti-B1 antibody, (131)I-tositumomab, anti-CD20 murine monoclonal antibody-I-131, B1, Bexxar, (131)I-anti-B1 antibody, iodine-131 tositumomab, iodine-131 anti-B1 antibody, tositumomab.
    BioDrugs; 2003; 17(4):290-5. PubMed ID: 12899647
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunochemotherapy: the new standard in aggressive non-Hodgkin's lymphoma in the elderly.
    Coiffier B
    Semin Oncol; 2003 Feb; 30(1 Suppl 2):21-7. PubMed ID: 12652461
    [TBL] [Abstract][Full Text] [Related]  

  • 17. First-line and maintenance treatment with rituximab for patients with indolent non-Hodgkin's lymphoma.
    Hainsworth JD
    Semin Oncol; 2003 Feb; 30(1 Suppl 2):9-15. PubMed ID: 12652459
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bendamustine for the treatment of chronic lymphocytic leukemia and rituximab-refractory, indolent B-cell non-Hodgkin lymphoma.
    Dennie TW; Kolesar JM
    Clin Ther; 2009; 31 Pt 2():2290-311. PubMed ID: 20110042
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rituximab, ofatumumab and other monoclonal anti-CD20 antibodies for chronic lymphocytic leukaemia.
    Bauer K; Rancea M; Roloff V; Elter T; Hallek M; Engert A; Skoetz N
    Cochrane Database Syst Rev; 2012 Nov; 11(11):CD008079. PubMed ID: 23152253
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bendamustine: a review of its use in the management of chronic lymphocytic leukaemia, rituximab-refractory indolent non-Hodgkin's lymphoma and multiple myeloma.
    Hoy SM
    Drugs; 2012 Oct; 72(14):1929-50. PubMed ID: 22950536
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 426.